Pharmaceutical composition for diabetic neuropathy
    1.
    发明申请
    Pharmaceutical composition for diabetic neuropathy 失效
    糖尿病性神经病的药物组合物

    公开(公告)号:US20050171051A1

    公开(公告)日:2005-08-04

    申请号:US11098439

    申请日:2005-04-05

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    Agent for improving learning or memory
    2.
    发明授权
    Agent for improving learning or memory 失效
    改善学习或记忆的代理

    公开(公告)号:US06803366B2

    公开(公告)日:2004-10-12

    申请号:US10148489

    申请日:2002-05-30

    IPC分类号: A61K314375

    摘要: Disclosed is an agent for improving learning and/or memory, which is useful for therapy of dementia accompanying disorder of memory due to a cerebrovascular disease, neurodegenerative disease such as Alzheimer's disease, endocrine disease, nutritional or metabolic disorder, infectious disease, drug addiction or the like. The agent for improving learning and/or memory according to the present invention comprises as an effective ingredient an isoquinoline derivative having a specific structure, such as (4aR, 12aR)-2-methyl-4a-(3-hydroxyphenyl)-1,2,3,4,4a,5,12,12a-octahydro-quinoline[2,3-g]isoquinoline or a pharmaceutically acceptable salt thereof.

    摘要翻译: 公开了一种用于改善学习和/或记忆的药剂,其用于治疗由于脑血管疾病,神经变性疾病如阿尔茨海默病,内分泌疾病,营养或代谢障碍,感染性疾病,药物成瘾引起的记忆障碍的痴呆症 类似。 根据本发明的用于改善学习和/或记忆的药剂包括作为有效成分的具有特定结构的异喹啉衍生物,例如(4aR,12aR)-2-甲基-4a-(3-羟基苯基)-1,2 ,3,4,4a,5,12,12a-八氢 - 喹啉[2,3-g]异喹啉或其药学上可接受的盐。

    Medicinal composition for drug-induced neuropathy
    4.
    发明申请
    Medicinal composition for drug-induced neuropathy 审中-公开
    药物性神经病变药物组成

    公开(公告)号:US20060094685A1

    公开(公告)日:2006-05-04

    申请号:US10520772

    申请日:2003-07-09

    IPC分类号: A61K31/7072

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of drug-induced neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of drug-induced neuropathy of the present invention shows a potent ameliorating effect on drug-induced neuropathy and is also superior in safety.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的药物性神经病的预防或治疗药物。 用于预防或治疗本发明的药物性神经病的药剂显示出对药物诱发的神经病变有效的改善效果,并且安全性也优异。

    Pharmaceutical composition for diabetic neuropathy
    6.
    发明授权
    Pharmaceutical composition for diabetic neuropathy 失效
    糖尿病性神经病的药物组合物

    公开(公告)号:US07074773B2

    公开(公告)日:2006-07-11

    申请号:US11098439

    申请日:2005-04-05

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    Antitussive
    7.
    发明授权
    Antitussive 失效
    镇咳药

    公开(公告)号:US5714483A

    公开(公告)日:1998-02-03

    申请号:US290837

    申请日:1994-10-13

    摘要: An antitussive having high activity, which is free from side effects such as psychotomimetic, which may also be administered orally is disclosed. The antitussive according to the present invention comprises as an effective ingredient a .delta.-opioid antagonist or a pharamaceutically acceptable salt thereof.

    摘要翻译: PCT No.PCT / JP93 / 01855 Sec。 371日期:1994年10月13日 102(e)日期1994年10月13日PCT 1993年12月22日PCT公布。 公开号WO94 / 14445 PCT 日期:1994年7月7日公开了一种具有高活性的镇咳药,其也没有副作用,如精神病药,也可以口服给药。 根据本发明的止咳剂包含作为有效成分的δ-阿片样拮抗剂或其药物上可接受的盐。

    Medicinal composition for diabetic neuropathy
    8.
    发明授权
    Medicinal composition for diabetic neuropathy 失效
    糖尿病性神经病变药物组成

    公开(公告)号:US06924272B2

    公开(公告)日:2005-08-02

    申请号:US10381716

    申请日:2002-09-03

    CPC分类号: C07H19/10 A61K31/7068

    摘要: The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5′-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration.

    摘要翻译: 本发明涉及含有胞苷5'-二磷酸胆碱(CDP-胆碱)作为活性成分的预防或治疗糖尿病性神经病的药剂。 用于预防或治疗本发明的糖尿病性神经病的药剂对于主要由碳水化合物的代谢紊乱引起的神经病有效,并且安全性也优异。 神经病包括周围神经病和自主神经病。 CDP-胆碱甚至通过口服给药也是有效的。

    Antitussives
    9.
    发明授权
    Antitussives 失效
    镇咳药

    公开(公告)号:US06337330B1

    公开(公告)日:2002-01-08

    申请号:US09254427

    申请日:1999-05-18

    IPC分类号: A61K31495

    CPC分类号: C07D471/04

    摘要: An antitussive agent containing an octahydroisoquinoline derivative represented by the following compound or pharmacologically acceptable acid addition salt thereof: The compounds of the present invention have the significant antitussive action, and can thus be expected as medicines which can be used for all diseases accompanied with coughs, for example, various respiratory diseases such as cold, acute bronchitis, chronic bronchitis, bronchiectasis, pneumonia, pulmonary tuberculosis, silicosis and silicotuberculosis, lung cancer, upper respiratory inflammation (pharyngitis, laryngitis, nasal catarrhalis), asthmatic bronchitis, bronchial asthma, infantile asthma, (chronic) pulmonary emphysema, pneumoconiosis, pulmonary fibrosis, silicosis, pulmonary suppuration, pleurisy, tonsillitis, tussive urticaria, pertussis, etc. and coughs caused in bronchography or bronchoscopy, etc.

    摘要翻译: 含有由以下化合物或其药理学上可接受的酸加成盐代表的八氢异喹啉衍生物的镇咳剂:本发明的化合物具有显着的镇咳作用,因此可以预期作为可用于伴有咳嗽的所有疾病的药物, 例如,感冒,急性支气管炎,慢性支气管炎,支气管扩张症,肺炎,肺结核,矽肺和硅肺结核等各种呼吸系统疾病,肺癌,上呼吸道炎症(咽炎,喉炎,鼻粘膜炎),哮喘性支气管炎,支气管哮喘,婴儿哮喘 ,慢性肺气肿,肺尘埃沉着病,肺纤维化,矽肺,肺部脓肿,胸膜炎,扁桃腺炎,咳嗽荨麻疹,百日咳等,以及支气管镜或支气管镜引起的咳嗽等。